Leuprolide Mesylate Drug Asset Due Diligence Report 2026

This Leuprolide Mesylate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Leuprolide Mesylate can convert its Small molecule drug profile and GnRHR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Leuprolide Mesylate (query alias: Leuprolide Mesylate)
Modality / target	Small molecule drug; GnRHR; GnRHR agonists
Highest global status	Approved
Originator	Foresee Pharmaceuticals Co., Ltd.
Active developers	Foresee Pharmaceuticals Co., Ltd., Accord BioPharma, Inc., Changchun Genescience Pharmaceuticals Co., Ltd.

The MCP disease footprint includes Advanced Prostate Carcinoma, Hormone-dependent prostate cancer, Prostatic Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07710430	Phase 4	Not yet recruiting	43	Peak luteinizing hormone (LH) level following gonadotropin-releasing hormone (GnRH) stimulation is < 4 International Units per Liter (IU/L).
NCT07159451	Phase 2	Recruiting	140	To determine if 4 weeks of elacestrant monotherapy determines a non-inferior anti-proliferative effect, measured by Ki67, in comparison to elacestrant with leuprorelin in premenopausal patients with ER-positive/HER2- operable invasive BC.
JPRN-jRCTs031260249	Phase 2	募集前	132	無増悪生存期間（PFS）：主たる解析対象集団を対象とし、無作為化日からPD又は理由を問わない死亡日のうち早い方までの期間とする。効果判定は、Response Evaluation Criteria in Solid Tumors （RECIST） Ver.1.1に準じて評価する。

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

POP-ELA: a short-term preoperative, phase II, window-of-opportunity study, evaluating activity and safety of Elacestrant with and without ovarian function suppression (OFS) in premenopausal patients with stage I–II HR+/HER2- breast cancer (BC)

Phase 2; n=140; evaluation: Positive. Reported fields: ER = 46.0 Pts ; -

An Open Label, Multicenter, Single-arm and Prospective Study to Assess the Efficacy and Safety of Leuprorelin 3M in the Treatment of Central Precocious Puberty (CPP)

Phase 4; n=80; evaluation: not stated. Reported fields: -; -; Percentage of Participants With Peak Luteinizing Hormone (LH) Suppression in Gonadotropin-Releasing Hormone (GnRH) Stimulation at Week 24 = 97.47 percentage of participants (95% Confidence Interval, 91.15 - 99.69)

FDA-Approved Drugs-CAMCEVI ETM-CLINICAL STUDIES

Phase 3; n=144; evaluation: Positive. Reported fields: medical castration rate(Week 4 through Week 24; maintainin serum testosterone suppression to < 50 ng/dL) = 97.2 % (95%CI, 92.7 - 98.9)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Leuprolide Mesylate addresses Advanced Prostate Carcinoma, Hormone-dependent prostate cancer, Prostatic Cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2021-03-04	Intas Pharmaceuticals to market FP-001 by Foresee Pharmaceuticals in the US.	NDA/BLA	US$10.0M upfront; US$207.0M milestones; US$217.0M stated total
2020-11-17	Foresee Pharmaceuticals Enters Exclusive License Agreement with GenSci for the Commercialization of Camcevi(TM) in China	NDA/BLA	US$8.0M upfront; US$123.8M milestones; US$131.8M stated total
2019-02-11	Foresee Pharmaceuticals Enters Exclusive License Agreement with Accord Healthcare	Phase 3	US$86.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.

Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers

Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.